Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$2.07 USD
+0.03 (1.47%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.07 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Coherus BioSciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 257 | 211 | 327 | 476 | 356 |
Cost Of Goods | 159 | 70 | 58 | 38 | 17 |
Gross Profit | 98 | 141 | 269 | 438 | 339 |
Selling & Adminstrative & Depr. & Amort Expenses | 301 | 398 | 533 | 282 | 231 |
Income After Depreciation & Amortization | -203 | -257 | -264 | 156 | 108 |
Non-Operating Income | 5 | -2 | 0 | 1 | 3 |
Interest Expense | 41 | 32 | 23 | 21 | 18 |
Pretax Income | -238 | -292 | -287 | 136 | 93 |
Income Taxes | 0 | 0 | 0 | 3 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -238 | -292 | -287 | 132 | 90 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -238 | -292 | -287 | 132 | 90 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -199 | -253 | -260 | 159 | 111 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 3 | 3 | 3 |
Income After Depreciation & Amortization | -203 | -257 | -264 | 156 | 108 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 94.16 | 77.63 | 75.45 | 83.49 | 73.19 |
Diluted EPS Before Non-Recurring Items | -2.43 | -3.68 | -3.81 | 1.62 | 1.23 |
Diluted Net EPS (GAAP) | -2.53 | -3.76 | -3.81 | 1.62 | 1.23 |
Fiscal Year end for Coherus BioSciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 91.52 | 74.57 | 58.72 | 32.44 |
Cost Of Goods | NA | 84.57 | 32.70 | 24.85 | 16.87 |
Gross Profit | NA | 6.96 | 41.87 | 33.87 | 15.56 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 75.86 | 73.87 | 68.41 | 83.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -68.90 | -32.00 | -34.54 | -67.74 |
Non-Operating Income | NA | -0.13 | 2.25 | 1.62 | 1.73 |
Interest Expense | NA | 10.62 | 10.27 | 9.94 | 9.71 |
Pretax Income | NA | -79.65 | -40.02 | -42.87 | -75.73 |
Income Taxes | NA | 0.00 | -0.38 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -79.65 | -39.64 | -42.87 | -75.73 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -79.65 | -39.64 | -42.87 | -75.73 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 111.49 | 97.74 | 87.27 | 79.27 |
Diluted EPS Before Non-Recurring Items | NA | -0.72 | -0.38 | -0.49 | -0.89 |
Diluted Net EPS (GAAP) | NA | -0.67 | -0.41 | -0.49 | -0.96 |